NEXICLON XR (clonidine) by Athena Bioscience is adrenergic alpha2-agonists [moa]. First approved in 2009.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
NEXICLON XR is an extended-release oral tablet formulation of clonidine, a central alpha-2 adrenergic agonist. It works by stimulating alpha-2 receptors in the brain to reduce sympathetic nervous system activity. The drug is indicated for hypertension management in adult patients requiring sustained blood pressure control.
Product is in peak lifecycle stage with minimal competitive pressure, suggesting stable but not high-growth commercial opportunities on the brand team.
Adrenergic alpha2-Agonists
Central alpha-2 Adrenergic Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.
Clonidine for Analgesia to Preterm Infants During Neonatal Intensive Care
Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants
Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients
Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers
Worked on NEXICLON XR at Athena Bioscience? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
NEXICLON XR shows minimal hiring momentum with only 1 linked job posting, concentrated in Risk/Collections functions rather than commercial or medical affairs. This signals a mature, operationally stable product with lower career growth potential.
1 open roles linked to this drug